Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells

[1]  R. Schreiber,et al.  Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. , 2001, Cancer research.

[2]  B. Klein,et al.  Inhibitors that target protein kinases for the treatment of ovarian carcinoma. , 2003, American journal of obstetrics and gynecology.

[3]  Jiayuh Lin,et al.  Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells , 2001, Oncogene.

[4]  J. McCune,et al.  A Membrane-bound Fas Decoy Receptor Expressed by Human Thymocytes* , 2000, The Journal of Biological Chemistry.

[5]  M. Hultén,et al.  Cytogenetics of a cell line derived from an ovarian papillary serous cystadenocarcinoma. , 1984, Cancer genetics and cytogenetics.

[6]  P. Chomczyński,et al.  Substitution of chloroform by bromo-chloropropane in the single-step method of RNA isolation. , 1995, Analytical biochemistry.

[7]  M. Hansen,et al.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. , 1989, Journal of immunological methods.

[8]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[9]  T. A. Connors,et al.  New platinum complexes with anti-tumour activity. , 1972, Chemico-biological interactions.

[10]  L. Kèlland,et al.  cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  K. Tarte,et al.  JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen‐activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells , 2000, British journal of haematology.

[12]  R. Shalaby,et al.  Alternatively Spliced Products CC3 and TC3 Have Opposing Effects on Apoptosis , 2000, Molecular and Cellular Biology.

[13]  S. Johnson,et al.  Recent insights into platinum drug resistance in cancer. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[14]  Yusuke Nakamura,et al.  An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. , 2002, Cancer research.

[15]  A. Godwin,et al.  A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. , 1993, European journal of cancer.

[16]  M. Bekradda,et al.  Oxaliplatin: a new therapeutic option in colorectal cancer. , 1999, Seminars in oncology.

[17]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. Kèlland,et al.  In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. , 1998, British Journal of Cancer.

[19]  W. Hiddemann,et al.  Constitutive activation of STAT transcription factors in acute myelogenous leukemia , 2001, European journal of haematology.

[20]  Christian A. Rees,et al.  Systematic variation in gene expression patterns in human cancer cell lines , 2000, Nature Genetics.

[21]  M. Tsuneyoshi,et al.  Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. , 2003, Cancer letters.

[22]  W. Leonard,et al.  Jaks and STATs: biological implications. , 1998, Annual review of immunology.

[23]  P B Laub,et al.  Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. , 1997, Cancer research.

[24]  L. Kèlland.  The Development of Orally Active Platinum Drugs , 2006 .

[25]  Bernhard Lippert,et al.  Cisplatin : chemistry and biochemistry of a leading anticancer drug , 2006 .

[26]  S. Pollefeyt,et al.  Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. , 2000, Blood.

[27]  A. Gao,et al.  Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. , 2000, Cancer research.

[28]  T. Niki,et al.  MSSP, a protein binding to an origin of replication in the c‐myc gene, interacts with a catalytic subunit of DNA polymerase α and stimulates its polymerase activity , 2000, FEBS letters.

[29]  K. Inagaki,et al.  Examination of antitumor activities of platinum complexes of 1,2-diaminocyclohexane isomers and their related complexes. , 1976, Gan.

[30]  Y. Furuta,et al.  Differentially expressed genes associated with CIS‐diamminedichloroplatinum (II) resistance in head and neck cancer using differential display and CDNA microarray , 2003, Head & neck.

[31]  J. Burchenal,et al.  1,2-Diaminocyclohexane platinum derivatives of potential clinical value. , 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[32]  Hua Yu,et al.  Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells , 2001, Oncogene.

[33]  R. Herbst,et al.  Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin. , 1997, In vivo.

[34]  K. Paull,et al.  Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. , 1996, Biochemical pharmacology.

[35]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.